Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two …
FC Mariz, P Gray, N Bender, T Eriksson… - The Lancet Infectious …, 2021 - thelancet.com
Background Quadrivalent and bivalent vaccines against oncogenic human papillomavirus
(HPV) are used worldwide with different reported overall efficacies against HPV infections …
(HPV) are used worldwide with different reported overall efficacies against HPV infections …
Correlating immunity with protection for HPV infection
I Frazer - International Journal of Infectious Diseases, 2007 - Elsevier
BACKGROUND: Cervical cancer is one of the most common types of cancer in women and
is largely attributable to persistent infection with high-oncogenic risk human papillomavirus …
is largely attributable to persistent infection with high-oncogenic risk human papillomavirus …
High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch …
R Donken, AJ King, JA Bogaards… - The Journal of …, 2018 - academic.oup.com
Background Monitoring vaccine effectiveness (VE) in vaccination programs is of importance
for assessing the impact of immunization. This study aimed to estimate the VE of the bivalent …
for assessing the impact of immunization. This study aimed to estimate the VE of the bivalent …
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Background The extent of cross-protection is a key element in the choice of human
papillomavirus (HPV) vaccine to use in vaccination programmes. We compared the cross …
papillomavirus (HPV) vaccine to use in vaccination programmes. We compared the cross …
[HTML][HTML] Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
S Joshi, D Anantharaman, R Muwonge, N Bhatla… - Vaccine, 2023 - Elsevier
Abstract Background The recent World Health Organization recommendation supporting
single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply …
single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply …
Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine
LL Villa - International Journal of Infectious Diseases, 2007 - Elsevier
BACKGROUND: Human papillomaviruses (HPVs) play an obligatory role in cervical cancer
devel-opment. Thus, immunization of women using a prophylactic vaccine against the most …
devel-opment. Thus, immunization of women using a prophylactic vaccine against the most …
Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis
K Cuschieri, K Kavanagh, C Moore, R Bhatia… - British journal of …, 2016 - nature.com
Background: Data on the effectiveness of one dose of HPV vaccine are lacking, particularly
in population-based settings. Data from a national HPV immunisation catch-up programme …
in population-based settings. Data from a national HPV immunisation catch-up programme …
Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent …
Background Limited data is available on the use of different HPV vaccines in the same
subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with …
subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with …
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15 …
H Sharma, S Parekh, P Pujari, S Shewale… - The Lancet …, 2023 - thelancet.com
Background To meet global cervical cancer elimination efforts, a wider range of affordable
and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to …
and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to …
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four …
SK Kjaer, M Nygård, K Sundström, J Dillner… - …, 2020 - thelancet.com
Background The quadrivalent human papillomavirus (qHPV) vaccine prevented vaccine
HPV type-related infection and disease in young women in the 4-year FUTURE II efficacy …
HPV type-related infection and disease in young women in the 4-year FUTURE II efficacy …